Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human
- PMID: 22143261
- DOI: 10.1007/s10928-011-9232-2
Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human
Abstract
The objectives of the following investigation were (1) development of a physiologically based pharmacokinetic (PBPK) model capable of characterizing the plasma and tissue pharmacokinetics (PK) of nonspecific or antigen specific monoclonal antibodies (mAbs) in wild type, FcRn knockout, tumor bearing and non tumor bearing mice and (2) evaluation of the scale up potential of the model by characterizing the mouse, rat, monkey and human plasma PK of mAbs, simultaneously. A PBPK model containing 15 tissues, a carcass and a tumor compartment was developed by modifying/augmenting previously published PBPK models. Each tissue compartment was subdivided into plasma, blood cell, endothelial, interstitial and cellular sub-compartments. Each tissue was connected through blood and lymph flow to the systemic circulation. Lymph flow was set to a value 500 times lower than plasma flow and vascular reflection coefficients for each tissue were adjusted according to their vascular pore size. In each tissue endothelial space, mAb entered via pinocytosis and the interaction of FcRn with mAb was described by on and off rates. FcRn bound mAb was recycled and unbound mAb was eliminated by a first order process (K(deg)). The PBPK model was simultaneously fit to the following datasets to estimate four system parameters: (1) plasma and tissue PK of nonspecific mAb in wild type mouse with or without simultaneous intravenous immunoglobulin (IVIG) administration, (2) plasma and tissue PK of nonspecific mAb in FcRn knockout mouse, (3) plasma and tissue PK of nonspecific mAb in tumor bearing mouse, (4) plasma and tissue PK of tumor antigen specific mAb in tumor bearing mouse, and (5) plasma PK of mAb in rat, monkey and human. The model was able to characterize all the datasets reasonably well with a common set of parameters. The estimated value of the four system parameters i.e. FcRn concentration (FcRn), rate of pinocytosis per unit endosomal space (CL(up)), K(deg) and the proportionality constant (C_LNLF) between the rate at which antibody transfers from the lymph node compartment to the blood compartment and the plasma flow of the given species, were found to be 4.98E-05 M (CV% = 11.1), 3.66E-02 l/h/l (%CV = 3.48), 42.9 1/h (%CV = 15.7) and 9.1 (CV% > 50). Thus, a platform PBPK model has been developed that can not only simultaneously characterize mAb disposition data obtained from various previously published mouse PBPK models but is also capable of characterizing mAb disposition in various preclinical species and human.
Similar articles
-
Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.AAPS J. 2014 Sep;16(5):1097-109. doi: 10.1208/s12248-014-9640-5. Epub 2014 Jul 9. AAPS J. 2014. PMID: 25004823 Free PMC article.
-
A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.AAPS J. 2018 Mar 14;20(3):48. doi: 10.1208/s12248-017-0183-4. AAPS J. 2018. PMID: 29541870 Free PMC article.
-
A translational platform PBPK model for antibody disposition in the brain.J Pharmacokinet Pharmacodyn. 2019 Aug;46(4):319-338. doi: 10.1007/s10928-019-09641-8. Epub 2019 May 21. J Pharmacokinet Pharmacodyn. 2019. PMID: 31115858 Free PMC article.
-
Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?Mol Immunol. 2013 Dec;56(4):660-74. doi: 10.1016/j.molimm.2013.05.008. Epub 2013 Aug 2. Mol Immunol. 2013. PMID: 23917469 Review.
-
Pharmacokinetic models for FcRn-mediated IgG disposition.J Biomed Biotechnol. 2012;2012:282989. doi: 10.1155/2012/282989. Epub 2012 May 14. J Biomed Biotechnol. 2012. PMID: 22665983 Free PMC article. Review.
Cited by
-
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data.J Pharmacokinet Pharmacodyn. 2022 Dec;49(6):579-592. doi: 10.1007/s10928-022-09823-x. Epub 2022 Sep 10. J Pharmacokinet Pharmacodyn. 2022. PMID: 36088452
-
Physiologically-based pharmacokinetic model for pulmonary disposition of protein therapeutics in humans.J Pharmacokinet Pharmacodyn. 2022 Dec;49(6):607-624. doi: 10.1007/s10928-022-09824-w. Epub 2022 Oct 20. J Pharmacokinet Pharmacodyn. 2022. PMID: 36266517 Free PMC article.
-
A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide.J Pharmacokinet Pharmacodyn. 2015 Apr;42(2):135-50. doi: 10.1007/s10928-015-9406-4. Epub 2015 Feb 4. J Pharmacokinet Pharmacodyn. 2015. PMID: 25650156
-
In Translation: FcRn across the Therapeutic Spectrum.Int J Mol Sci. 2021 Mar 17;22(6):3048. doi: 10.3390/ijms22063048. Int J Mol Sci. 2021. PMID: 33802650 Free PMC article. Review.
-
A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs.Front Bioinform. 2021 Sep 3;1:731340. doi: 10.3389/fbinf.2021.731340. eCollection 2021. Front Bioinform. 2021. PMID: 36303796 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources